SCHEMBL13620617

SCHEMBL13620617

CC(=O)Oc1ccc2c(c1)Oc1cc(OC(C)=O)ccc1C21OC(=O)c2ccc(C(C)=O)cc21

nearest known ligand 0.75

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 4/20 0.75
KMT2A Q03164 4/20 0.75
MAPT P10636 3/20 0.75
HTT P42858 2/20 0.75
USP2 O75604 2/20 0.75
ALDH1A1 P00352 2/20 0.75
LMNA P02545 1/20 0.75
GSTP1 P09211 1/20 0.64
CYP3A4 P08684 1/20 0.51
FTO Q9C0B1 8/20 0.46
RECQL P46063 2/20 0.45
HPGD P15428 1/20 0.45
CYP2C19 P33261 1/20 0.45
BLM P54132 1/20 0.45
SMAD3 P84022 1/20 0.45
PRMT1 Q99873 1/20 0.45
ACE2 Q9BYF1 1/20 0.45
TDP1 Q9NUW8 1/20 0.45
GAPDH P04406 2/20 0.38
SMN1; SMN2 Q16637 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29349471 0.92 MEN1 (0.73) MEN1KMT2AMAPTHTTUSP2
SCHEMBL5277430 0.92 MEN1 (0.73) MEN1KMT2AMAPTHTTUSP2
SCHEMBL30112719 0.92 MEN1 (0.73) MEN1KMT2AMAPTHTTUSP2
SCHEMBL18677730 0.92 MAPT (0.77) MEN1KMT2AMAPTHTTUSP2
SCHEMBL30224109 0.89 MEN1 (0.72) MEN1KMT2AMAPTHTTUSP2
SCHEMBL1503778 0.87 MAPT (0.67) MEN1KMT2AMAPTHTTUSP2
SCHEMBL30112591 0.87 MEN1 (0.67) MEN1KMT2AMAPTHTTUSP2
SCHEMBL13620842 0.87 MAPT (0.77) MEN1KMT2AMAPTHTTUSP2
SCHEMBL14771618 0.86 MEN1 (0.75) MEN1KMT2AMAPTHTTUSP2
SCHEMBL14771617 0.86 MEN1 (0.75) MEN1KMT2AMAPTHTTUSP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1204430-B1 CONJUGATES AND METHODS FOR THE PRODUCTION THEREOF, AND THEIR USE FOR TRANSPORTING MOLECULES VIA BIOLOGICAL MEMBRANES SANOFI AVENTIS DEUTSCHLAND (DE) 2009-11-04 EP disclosed
US-20080071069-A1 CONJUGATES AND PROCESSES FOR THEIR PREPARATION AND THEIR USE FOR TRANSPORTING MOLECULES ACROSS BIOLOGICAL MEMBRANES SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2008-03-20 US disclosed
US-20080071069-A1 CONJUGATES AND PROCESSES FOR THEIR PREPARATION AND THEIR USE FOR TRANSPORTING MOLECULES ACROSS BIOLOGICAL MEMBRANES SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2008-03-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080071069-A1 CONJUGATES AND PROCESSES FOR THEIR PREPARATION AND THEIR USE FOR TRANSPORTING MOLECULES ACROSS BIOLOGICAL MEMBRANES EPCAM, ABCB1, ABCB11 MEN1 877/4885KMT2A 4460/4885MAPT 2324/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.